Key result
Hemodialysis induced arteriovenous differences in several cytochrome P450 epoxy metabolites immediately after treatment, driven by decreased soluble epoxide hydrolase activity.
Why the study?
Factors causing increased cardiovascular morbidity and mortality in hemodialysis patients are largely unknown, and the impact of hemodialysis on arterial versus venous oxylipins required further evaluation.
Does hemodialysis alter the arteriovenous differences of plasma oxylipins in patients with end-stage renal disease?
Observational (n=12)
Does hemodialysis alter the arteriovenous differences of plasma oxylipins in patients with end-stage renal disease?
Hemodialysis acutely alters CYP epoxy metabolites in the peripheral circulation, which may contribute to the increased cardiovascular morbidity observed in ESRD patients.
Factors causing the increased cardiovascular morbidity and mortality in hemodialysis (HD) patients are largely unknown. Oxylipins are a superclass of lipid mediators with potent bioactivities produced from oxygenation of polyunsaturated fatty acids. We previously assessed the impact of HD on oxylipins in arterial blood plasma and found that HD increases several oxylipins. To study the phenomenon further, we now evaluated the differences in arterial and venous blood oxylipins from patients undergoing HD. We collected arterial and venous blood samples in upper extremities from 12 end-stage renal disease (ESRD) patients before and after HD and measured oxylipins in plasma by LC-MS/MS tandem mass spectrometry. Comparison between cytochrome P450 (CYP), lipoxygenase (LOX), and LOX/CYP ω/(ω-1)-hydroxylase metabolites levels from arterial and venous blood showed no arteriovenous differences before HD but revealed arteriovenous differences in several CYP metabolites immediately after HD. These changes were explained by metabolites in the venous blood stream of the upper limb. Decreased soluble epoxide hydrolase (sEH) activity contributed to the release and accumulation of the CYP metabolites. However, HD did not affect arteriovenous differences of the majority of LOX and LOX/CYP ω/(ω-1)-hydroxylase metabolites. The HD treatment itself causes changes in CYP epoxy metabolites that could have deleterious effects in the circulation.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) conducted an observational in End-stage renal disease (ESRD) (n=12). Hemodialysis vs. Before hemodialysis was evaluated on Differences in arterial and venous blood oxylipins. Hemodialysis induced arteriovenous differences in several cytochrome P450 epoxy metabolites immediately after treatment, driven by decreased soluble epoxide hydrolase activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: